Last reviewed · How we verify
Insulin Lispro Protamine Suspension
Insulin lispro protamine suspension is a long-acting basal insulin that binds to insulin receptors on muscle and fat cells to promote glucose uptake and storage, lowering blood glucose levels.
Insulin lispro protamine suspension is a long-acting basal insulin that binds to insulin receptors on muscle and fat cells to promote glucose uptake and storage, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Lispro Protamine Suspension |
|---|---|
| Also known as | LY275585[P], Insulin Lispro Protamine Suspension (ILPS), Neutral Protamine Lispro (NPL), Humalog, ILPS |
| Sponsor | Eli Lilly and Company |
| Drug class | Basal insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin lispro is a rapid-acting insulin analog that is combined with protamine to create a suspension that extends its duration of action to provide basal (background) insulin coverage. The protamine delays absorption of the insulin lispro, allowing it to work over approximately 24 hours. This formulation helps maintain steady glucose control between meals and overnight in patients with diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes (PHASE4)
- Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies (PHASE4)
- A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus (PHASE4)
- A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients (PHASE3)
- Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment (PHASE3)
- Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide (PHASE3)
- Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes (PHASE3)
- Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Lispro Protamine Suspension CI brief — competitive landscape report
- Insulin Lispro Protamine Suspension updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI